404 related articles for article (PubMed ID: 23197039)
21. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
22. Tankyrase: a promising therapeutic target with pleiotropic action.
Sagathia V; Patel C; Beladiya J; Patel S; Sheth D; Shah G
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3363-3374. PubMed ID: 37338576
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length.
Rippmann JF; Damm K; Schnapp A
J Mol Biol; 2002 Oct; 323(2):217-24. PubMed ID: 12381316
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
25. Tankyrase is necessary for canonical Wnt signaling during kidney development.
Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
[TBL] [Abstract][Full Text] [Related]
26.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of tankyrase activation by polymerization.
Pillay N; Mariotti L; Zaleska M; Inian O; Jessop M; Hibbs S; Desfosses A; Hopkins PCR; Templeton CM; Beuron F; Morris EP; Guettler S
Nature; 2022 Dec; 612(7938):162-169. PubMed ID: 36418402
[TBL] [Abstract][Full Text] [Related]
28. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of tankyrase inhibition in whole cells.
Ohishi T; Tsuruo T; Seimiya H
Methods Mol Biol; 2007; 405():133-46. PubMed ID: 18369822
[TBL] [Abstract][Full Text] [Related]
30. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
31. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
32. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
33. Identifying and Validating Tankyrase Binders and Substrates: A Candidate Approach.
Pollock K; Ranes M; Collins I; Guettler S
Methods Mol Biol; 2017; 1608():445-473. PubMed ID: 28695526
[TBL] [Abstract][Full Text] [Related]
34. Biochemical Analysis of Tankyrase Activity in Zebrafish In Vitro and In Vivo.
Moon J; Amatruda JF
Methods Mol Biol; 2016; 1481():95-100. PubMed ID: 27590155
[TBL] [Abstract][Full Text] [Related]
35. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
36. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
37. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
38. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
39. Tankyrase inhibition aggravates kidney injury in the absence of CD2AP.
Kuusela S; Wang H; Wasik AA; Suleiman H; Lehtonen S
Cell Death Dis; 2016 Jul; 7(7):e2302. PubMed ID: 27441654
[TBL] [Abstract][Full Text] [Related]
40. Homogeneous screening assay for human tankyrase.
Narwal M; Fallarero A; Vuorela P; Lehtiö L
J Biomol Screen; 2012 Jun; 17(5):593-604. PubMed ID: 22357873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
